Shared on 29 Jul 25
Fair value Increased 11%The increased consensus price target for AbCellera Biologics is primarily supported by a higher future P/E ratio—implying stronger growth expectations—resulting in an upward revision from $8.43 to $9.14. What's in the News AbCellera received a No Objection Letter from Health Canada for its Clinical Trial Application for ABCL575, an antibody targeting OX40L for atopic dermatitis and other inflammatory conditions; Phase 1 study to begin in Q3 2025.